Abstract
Introduction
Proton beam therapy has been utilised for the treatment of uveal melanoma in the UK for over 30 years, undertaken under a single centre. In the UK, all ocular tumours are treated at one of four centres. We aimed to understand the variation in referral patterns to the UK proton service, capturing all uveal melanoma patients treated with this modality.
Methods
Retrospective analysis of data regarding all patients treated at the Clatterbridge Proton service between January 2004 and December 2014.
Results
A total of 1084 patients with uveal melanoma were treated. The mean age was 57 years (range 9–90 years), basal diameter of 11.5 mm (range 2.0–23.4 mm) and tumour thickness of 3.9 mm (range 0.1–15.4 mm). The majority were TNM stage I (39%) or II (36%). The distance to the optic nerve varied from 0 to 24.5 mm with 148 (14%) of patients having ciliary body involvement. There were variations in the phenotypic characteristic of the tumours treated with protons from different centres, with London referring predominantly small tumours at the posterior pole, Glasgow referring large tumours often at the ciliary body and Liverpool sending a mix of these groups.
Discussion
In the UK, common indications for the use of proton treatment in uveal melanoma include small tumours in the posterior pole poorly accessible for plaque treatment (adjacent to the disc), tumours at the posterior pole affecting the fovea and large anterior tumours traditionally too large for brachytherapy. This is the first UK-wide audit enabling the capture of all patients treated at the single proton centre.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Data availability
Raw data are available on request.
References
Durante M, Orecchia R, Loeffler JS. Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol. 2017;14:483–95.
Goossens ME, Van den Bulcke M, Gevaert T, Meheus L, Verellen D, Cosset JM, et al. Is there any benefit to particles over photon radiotherapy? Ecancermedicalscience. 2019;13:982.
Schreuder AN, Shamblin J. Proton therapy delivery: what is needed in the next ten years? Br J Radio. 2020;93:20190359.
Burnet NG, Mackay RI, Smith E, Chadwick AL, Whitfield GA, Thomson DJ, et al. Proton beam therapy: perspectives on the National Health Service England clinical service and research programme. Br J Radio. 2020;93:20190873.
Gragoudas ES, Goitein M, Koehler AM, Verhey L, Tepper J, Suit HD, et al. Proton irradiation of small choroidal malignant melanomas. Am J Ophthalmol. 1977;83:665–73.
Hrbacek J, Mishra KK, Kacperek A, Dendale R, Nauraye C, Auger M, et al. Practice patterns analysis of ocular proton therapy centers: the International OPTIC Survey. Int J Radiat Oncol Biol Phys. 2016;95:336–43.
Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radio). 2016;28:e17–27.
Wang Z, Nabhan M, Schild SE, Stafford SL, Petersen IA, Foote RL, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:18–26.
Boldt HC, Binkley E. Treating small choroidal melanoma: smaller is better. JAMA Ophthalmol. 2018;136:1333–4.
Hussain R, Czanner G, Taktak A, Damato B, Praidou A, Heimann H. Mortality of patients with uveal melanoma detected by diabetic retinopathy screening. Retina. 2020;40:2198–2206.
Jouhi S, Jager MJ, de Geus SJR, Desjardins L, Eide NA, Grange JD, et al. The Small Fatal Choroidal Melanoma Study. A survey by the European Ophthalmic Oncology Group. Am J Ophthalmol. 2019;202:100–8.
Toutee A, Angi M, Dureau S, Levy-Gabriel C, Rouic LL, Dendale R, et al. Long-term visual outcomes for small uveal melanoma staged T1 treated by proton beam radiotherapy. Cancers (Basel). 2019;11:1047.
Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys. 2005;63:385–91.
Kacperek A. Protontherapy of eye tumours in the UK: a review of treatment at Clatterbridge. Appl Radiat Isot. 2009;67:378–86.
Sikuade MJ, Salvi S, Rundle PA, Errington DG, Kacperek A, Rennie IG. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma. Eye (Lond). 2015;29:1194–8.
Mishra KK, Daftari IK. Proton therapy for the management of uveal melanoma and other ocular tumors. Chin Clin Oncol. 2016;5:50.
Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, Cassoux N, Dendale R, Mazal A, et al. Treatment of uveal melanoma by accelerated proton beam. Dev Ophthalmol. 2012;49:41–57.
Kamran SC, Collier JM, Lane AM, Kim I, Niemierko A, Chen YL, et al. Outcomes of proton therapy for the treatment of uveal metastases. Int J Radiat Oncol Biol Phys. 2014;90:1044–50.
Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys. 2005;62:1405–11.
Egger E, Zografos L, Schalenbourg A, Beati D, Bohringer T, Chamot L, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;55:867–80.
Egger E, Zografos L, Munkel G, Bohringer T, Bercher L, Chamot L. Results of proton radiotherapy for uveal melanomas. Front Radiat Ther Oncol. 1997;30:111–22.
Gragoudas ES. 1996 Jules Gonin Lecture of the Retina Research Foundation. Long-term results after proton irradiation of uveal melanomas. Graefes Arch Clin Exp Ophthalmol. 1997;235:265–7.
Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, Dendale R, Delacroix S, Nauraye C, et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res. 2006;38:255–60.
Pica A, Weber DC, Vallat L, Bergin C, Hrbacek J, Schweizer C, et al. Good long-term visual outcomes of parapapillary choroidal melanoma patients treated with proton therapy: a comparative study. Int Ophthalmol. 2021;41:441–52.
Thariat J, Grange JD, Mosci C, Rosier L, Maschi C, Lanza F, et al. Visual outcomes of parapapillary uveal melanomas following proton beam therapy. Int J Radiat Oncol Biol Phys. 2016;95:328–35.
Hussain R, Heussen FM, Heimann H. OCT changes in peri-tumour normal retina following ruthenium-106 and proton beam radiotherapy for uveal melanoma. Br J Ophthalmol. 2021;105:648–52.
Author information
Authors and Affiliations
Contributions
All authors have contributed to the conceptualisation of this paper, data collection, data analysis and/or write-up of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hussain, R.N., Chiu, A., Pittam, B. et al. Proton beam radiotherapy for choroidal and ciliary body melanoma in the UK—national audit of referral patterns of 1084 cases. Eye 37, 1033–1036 (2023). https://doi.org/10.1038/s41433-022-02178-0
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-022-02178-0
This article is cited by
-
Artificial intelligence with ChatGPT 4: a large language model in support of ocular oncology cases
International Ophthalmology (2025)
-
Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma
Eye (2024)
-
Ocular oncology demystified
Eye (2023)
